By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Your Profits Grow Sky High.

Zika Virus: Testing for Austria vaccine begins

logo Themis © Themis

The clinical study will focus on identifying the most suitable doses of the vaccine candidate in regard to immunogenicity, safety, and tolerability. Therefore up to 48 healthy volunteers will participate in the study and three different treatment regimens will be compared with a placebo treatment. One treatment group will receive one injection of high dose vaccine, the other two groups will receive two shots of either high dose or low dose vaccine. Results of all groups are expected within the next six months. The study will be conducted at the "Department of Clinical Pharmacology" and the "Institute of Specific Prophylaxis and Tropical Medicine" at the Medical University of Vienna, Austria.

Zika is a viral infection transmitted by mosquitoes. It originates in Asia and parts of Africa but the increase in global traveling and rising temperatures may cause it to spread into more temperate zones. Recently, the virus spread across the Pacific Ocean to the Americas, leading to the 2015/16 virus epidemic.

About Themis

Themis Bioscience GmbH develops prophylactic vaccines from the preclinical to the early clinical phase, focusing on emerging tropical infectious diseases, with initial vaccine candidates currently being developed against Chikungunya and Zika. The company's highly innovative and fully patent-protected measles virus vaccine vector technology platform, licensed from the internationally respected Institut Pasteur in Paris, forms the basis for all current vaccine candidates of the Vienna-based company.
www.themisbio.com

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • ABA's Virtual Open Day Reloaded

    01.10.2020/ 14pm - 15pm (CET), Virtual Event

  • Austria - Oportunități pentru companii românești

    05.10.2020/ | 16:30 - 18:30, București, Romania

Austria Map

Find the perfect location for your company

Austria stands out due to its long-term reliable and stable conditions. These features are particularly important for a research-based company such as Boehringer Ingelheim. Furthermore, Vienna is a city with a good research infrastructure and a high quality of life, and is thus also an interesting place for highly qualified employees from Austria and abroad.

Boehringer Ingelheim

Logo
More testimonials

news from the business location Austria

Investment for augmented reality startup Amlogy

Augmented reality (AR) has always been a passion for Arkadi Jeghiazaryan.

Innovations from Vienna are a Growth Driver

Multinational companies invest € 2 billion in research in Austria every year. Many of the subsidiaries based in Austria carry out research and development activities in the Alpine Republic. Our company also does so. Ottobock has been operating in Austria for more than 50 years.

More news All blog posts